Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials
出版年份 2021 全文链接
标题
Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials
作者
关键词
-
出版物
INTERNATIONAL UROLOGY AND NEPHROLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-06
DOI
10.1007/s11255-021-02820-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
- (2019) Keitaro Yokoyama et al. Scientific Reports
- Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients
- (2018) Noriaki Maruyama et al. AMERICAN JOURNAL OF NEPHROLOGY
- Current and potential treatment options for hyperphosphatemia
- (2018) Fabio Carfagna et al. Expert Opinion On Drug Safety
- Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients
- (2018) Stuart M. Sprague et al. Hemodialysis International
- Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease
- (2018) Norishi Ueda et al. Nutrients
- Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study
- (2017) Fumihiko Koiwa et al. NEPHROLOGY
- Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
- (2017) Ashraf Mikhail et al. BMC Nephrology
- Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
- (2016) Fumihiko Koiwa et al. Clinical and Experimental Nephrology
- The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial
- (2015) Peter N. Van Buren et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5
- (2015) Geoffrey A. Block et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis
- (2015) Sarah L. Greig et al. DRUGS
- Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
- (2015) J. Floege et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study
- (2014) Chien-Te Lee et al. JOURNAL OF NEPHROLOGY
- Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis
- (2014) J. B. Lewis et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
- (2014) Jürgen Floege et al. KIDNEY INTERNATIONAL
- Gastrointestinal symptoms: A comparison between patients undergoing peritoneal dialysis and hemodialysis
- (2014) Rui Dong WORLD JOURNAL OF GASTROENTEROLOGY
- Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data
- (2014) Marvin Sinsakul et al. Expert Review of Clinical Pharmacology
- Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy
- (2013) Masafumi Fukagawa et al. Clinical and Experimental Nephrology
- A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis
- (2013) K. Yokoyama et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of Oral JTT-751 (Ferric Citrate) on Hyperphosphatemia in Hemodialysis Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
- (2012) Keitaro Yokoyama et al. AMERICAN JOURNAL OF NEPHROLOGY
- Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients
- (2012) R. P. Wuthrich et al. Clinical Journal of the American Society of Nephrology
- Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride
- (2011) JIN-BOR CHEN et al. NEPHROLOGY
- Efficacy and safety of SBR759, a new iron-based phosphate binder
- (2010) Geoffrey A. Block et al. KIDNEY INTERNATIONAL
- Iron-Magnesium Hydroxycarbonate (Fermagate): A Novel Non-Calcium-Containing Phosphate Binder for the Treatment of Hyperphosphatemia in Chronic Hemodialysis Patients
- (2009) C. W. McIntyre et al. Clinical Journal of the American Society of Nephrology
- Lanthanum Carbonate Effectively Controls Serum Phosphate Without Affecting Serum Calcium Levels in Patients Undergoing Hemodialysis
- (2008) Takashi Shigematsu et al. THERAPEUTIC APHERESIS AND DIALYSIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now